Viking Therapeutics (VKTX)

AI Summary

Argues VK2735's registration case rests on 78-week durability/safety and maintenance data rather than beating semaglutide/tirzepatide on peak weight loss.

VKTX — WATCH The author argues VK2735 does not need to beat semaglutide or tirzepatide on peak one-year weight loss; registration will depend on long-duration (78-week) weight loss, safety/tolerability, and maintenance across subcutaneous and oral formulations. Phase 3 VANQUISH trials and the maintenance protocol are the concrete catalysts that will decide this. The main stated risk is higher discontinuations due to adverse events in the oral VENTURE study.

If you want to critique Viking, the right scientific targets are: 78 week WL magnitude, discontinuation rate, GI AE profile, and exposure response across doses and formulations. That is what the data will settle.

▶ Full Post Text

The development question is not “can it beat sema or tirz on peak WL at 1 year” because those benchmarks are already very high. The question is whether VK2735 can deliver a clinically meaningful ETA profile that holds up in long duration use, which is exactly what Phase 3 is designed to test.

Facts on Viking’s program design:

1. **Pivotal scale and duration are not small biotech hand waving**. VK2735 SC is in two randomized, double blind, placebo controlled Phase 3 trials dosed weekly for **78 weeks**. VANQUISH 1 has enrolled \~**4,650** adults and VANQUISH 2 targets \~**1,100** adults with T2D. Arms include **7.5, 12.5, 17.5 mg** and placebo. That is a standard registration design and sample size class.
2. “Maintenance” is being tested as an actual protocol, not a talking point. Viking is running a randomized, double blind Phase 1 maintenance study in \~**180** adults: **19 weeks induction** with weekly SC VK2735 or placebo, then transition to **monthly SC**, **daily oral**, **weekly oral**, or placebo through **Week 31**, with PK and safety primary and body weight exploratory.
3. Oral efficacy signal exists, with known limitations. In VENTURE Oral, top line reporting shows up to **12.2% mean weight loss at 13 weeks** with dose response and a step down cohort (90 mg to 30 mg) explored for maintenance feasibility. Discontinuations due to AEs were reported as higher than placebo, which is a real development risk that Phase 3 durability and tolerability will adjudicate.

Competition framing: yes, if VK2735 cannot approach class-leading efficacy at acceptable tolerability over 78 weeks, it will not matter. But it is not scientifically correct to claim the only viable strategy is “beat peak WL or run MACE.” Registration is built on long duration weight loss and safety; event driven outcomes are typically lifecycle programs.

If you want to critique Viking, the right scientific targets are: 78 week WL magnitude, discontinuation rate, GI AE profile, and exposure response across doses and formulations. That is what the data will settle.

▶ Full Post Text

Ideas

More from Reddit — r/biotech_stocks